Vir Biotechnology reported Q3 2023 losses of $(1.22) per share, missing the analyst consensus estimate of $(1.21) by 0.83 percent. This is a 193.85 percent decrease over earnings of $1.30 per share from the same period last year. The company also reported quarterly sales of $2.64 million, missing the analyst consensus estimate of $10.24 million by 74.23 percent, a 99.30 percent decrease over sales of $374.56 million the same period last year.